This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dyax And Eclipse Therapeutics Announce Oncology Antibody License Agreement

Dyax Corp. (NASDAQ:DYAX) and Eclipse Therapeutics, Inc., a privately held oncology company, announced today that Dyax has granted Eclipse an exclusive worldwide license for the development and commercialization of preclinical fully-human antibodies discovered using Dyax’s gold-standard phage display technology for use in oncology indications. In exchange, Dyax will receive an initial license fee, payments upon the achievement of clinical development and sales milestones, and royalties on worldwide net sales resulting from commercialized products.

“We are excited to license this program to Eclipse, a leader in the development of innovative therapies that target cancer stem cells. This agreement reflects our strategy to maximize the value of our technology by partnering with companies that have a unique expertise to drive the development of promising antibody drug candidates,” stated Gustav A. Christensen, President and Chief Executive Officer of Dyax. “This agreement further underscores the significant long-term potential of our robust licensing and funded research program, which continues to be a key driver of near- and long-term value creation for Dyax with 18 therapeutic candidates currently in the clinic, including four in Phase 3 and four in Phase 2.”

“This agreement provides Eclipse with multiple high-value antibody candidates targeting cancer stem cells (CSC) developed using Eclipse’s unique CSC Rx Discovery™ platform and Dyax’s proven phage display technology,” stated Peter Chu, Ph.D., President and Co-founder of Eclipse. “Our oncology pipeline focuses on identifying functional therapeutics that specifically inhibit CSC targets critical to the maintenance of cancer stem cells at the root of cancer. Dyax’s expertise in antibody therapeutic discovery accelerates these efforts, allowing us to expand our library of product candidates.”

About Dyax’s Phage Display

Dyax’s phage display technology has powered therapeutic and diagnostic candidate discovery across a wide range of therapeutic areas. For more than 15 years, Dyax has developed and improved the tools that enable the effective and rapid screening of its proprietary, state-of-the-art, antibody or peptide libraries, each containing billions of members to identify candidate molecules fitting exacting and challenging sets of lead candidate criteria.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs